Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326851 | 1.00 | TSHR (0.44) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL21239569 | 0.84 | TSHR (0.56) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL8183880 | 0.84 | CA1 (0.46) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL7334524 | 0.83 | TSHR (0.47) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL10467869 | 0.83 | TSHR (0.47) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL10467753 | 0.83 | TSHR (0.47) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL12444919 | 0.80 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12444920 | 0.80 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9449354 | 0.80 | TSHR (0.50) | TSHRHTTCA1CA2CA7 | |
| SCHEMBL10508626 | 0.80 | TSHR (0.50) | TSHRHTTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| CN-101679213-A | New methods | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2142497-A1 | NEW METHODS | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119804-A1 | NEW METHODS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119804-A1 | NEW METHODS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130749-A1 | METHODS | REN, AGTR1, AGTR2 | TSHR 1981/4885HTT 2250/4885CA1 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.